CompletedPhase 4ACTRN12610000835044
Influence on hemodynamics of conversion from Calcineurin Inhibitor to Sirolimus in Renal and Liver Transplant patients
Influence on hemodynamics of conversion from Calcineurin Inhibitor to Sirolimus in Renal and Liver Transplant patients older than 18 year
Sponsor
University Hospital Bern
Enrollment
40 participants
Start Date
Sep 1, 2004
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria2
- renal of liver allograft recipient
- creatinine clearance > 30ml/min
Exclusion Criteria5
- signs of acute rejection
- evidence of active systemic or localised major infection
- known or suspected malignancy ( exception skin malignancies)
- renal arterial stenosis > 50 % reduction in luminal diameter
- hydronephros
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Switch calcineurin inhibitor (CNI) to Sirolimus treatment;
Sirolimus dose:Loading dose 10-15 mg/d (at clinicians discretion); d 2-6:3-5 mg/d (at clinicians discretion), after d 7,sirolimus dosage was
Switch calcineurin inhibitor (CNI) to Sirolimus treatment; Sirolimus dose:Loading dose 10-15 mg/d (at clinicians discretion); d 2-6:3-5 mg/d (at clinicians discretion), after d 7,sirolimus dosage was adjusted to target through level of 6–16 ng/mL study duration: 1 year. administration: oral capsule
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000835044